PPARγ agonists have been shown to reduce blood glucose and insulin resistance, by comparing the effect of TNF-α in adipocytes, with potential therapeutic targets for obesity, dyslipidemia and diabetes. This evidence concerns the gene TNF and obesity due to melanocortin 4 receptor deficiency.